[go: up one dir, main page]

ZA200703908B - Compositions for HCV treatment - Google Patents

Compositions for HCV treatment

Info

Publication number
ZA200703908B
ZA200703908B ZA200703908A ZA200703908A ZA200703908B ZA 200703908 B ZA200703908 B ZA 200703908B ZA 200703908 A ZA200703908 A ZA 200703908A ZA 200703908 A ZA200703908 A ZA 200703908A ZA 200703908 B ZA200703908 B ZA 200703908B
Authority
ZA
South Africa
Prior art keywords
compositions
hcv treatment
hcv
treatment
Prior art date
Application number
ZA200703908A
Other languages
English (en)
Inventor
Lin Kai
Weidmann Beat
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200703908B publication Critical patent/ZA200703908B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA200703908A 2004-12-23 2007-05-15 Compositions for HCV treatment ZA200703908B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63867504P 2004-12-23 2004-12-23

Publications (1)

Publication Number Publication Date
ZA200703908B true ZA200703908B (en) 2009-06-24

Family

ID=36155247

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703908A ZA200703908B (en) 2004-12-23 2007-05-15 Compositions for HCV treatment

Country Status (16)

Country Link
US (1) US7897565B2 (xx)
EP (1) EP1830871A1 (xx)
JP (1) JP2008525459A (xx)
KR (1) KR20070087624A (xx)
CN (1) CN101076350A (xx)
AU (1) AU2005322242B2 (xx)
BR (1) BRPI0519345A2 (xx)
CA (1) CA2587793A1 (xx)
IL (1) IL183659A0 (xx)
MA (1) MA29098B1 (xx)
MX (1) MX2007007779A (xx)
NO (1) NO20073764L (xx)
NZ (1) NZ555143A (xx)
RU (1) RU2007128099A (xx)
WO (1) WO2006071619A1 (xx)
ZA (1) ZA200703908B (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
KR20070036175A (ko) 2004-07-14 2007-04-02 노파르티스 아게 Ｃ형 간염(ｈｃｖ)의 치료를 위한 시클로스포린과ｐｅｇ화된 인터페론의 조합 제제의 용도
AU2005322241B2 (en) * 2004-12-23 2010-02-18 Novartis Ag Compounds for flaviviridae treatment
WO2006071619A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment
CA2611151A1 (en) * 2005-06-17 2006-12-28 Novartis Ag Use of sanglifehrin in hcv
CA2615626A1 (en) * 2005-07-18 2007-01-25 Novartis Ag Small animal model for hcv replication
ATE498630T1 (de) 2005-09-30 2011-03-15 Scynexis Inc Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
CN105169369B (zh) 2005-09-30 2019-10-18 中美华世通生物医药科技（武汉）有限公司 治疗和预防丙型肝炎感染的方法和药物组合物
JP2007112775A (ja) * 2005-10-24 2007-05-10 Hamamatsu Univ School Of Medicine サイトメガロウイルス感染の処置におけるシクロスポリン類の使用
JP5377293B2 (ja) 2006-05-19 2013-12-25 スシネキス インク 眼疾患の治療及び予防方法
AU2007306316B2 (en) * 2006-10-12 2011-10-27 Kyushu University Use of modified cyclosporins
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
CA2724523A1 (en) 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
CN102307892A (zh) 2008-12-31 2012-01-04 西尼克斯公司 环孢菌素a的衍生物
US10752611B2 (en) 2009-02-27 2020-08-25 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
AU2010313497B2 (en) 2009-10-30 2013-08-01 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
PH12012501216A1 (en) * 2009-12-18 2012-11-05 Boehringer Ingelheim Int Hcv combination therapy
AU2011311706B2 (en) 2010-10-05 2015-11-12 Debiopharm S.A. New treatments of Hepatitis C virus infection
JP6110791B2 (ja) 2010-11-30 2017-04-05 ノバルティス アーゲー Ｃ型肝炎ウイルス感染症の新規治療
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
MX2013011256A (es) 2011-03-31 2013-10-17 Novartis Ag Alisporivir para el tratamiento de la infeccion por el virus de hepatitis c.
RU2013148779A (ru) 2011-04-01 2015-05-10 Новартис Аг Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
US20150104415A1 (en) 2011-04-13 2015-04-16 Debiopharm International Sa Treatments of Hepatitis C virus infection
AU2012314517A1 (en) 2011-09-27 2014-04-17 Novartis Ag Alisporivr for treatment of Hepatis C virus infection
CN104284671A (zh) 2012-05-07 2015-01-14 诺华股份有限公司 使用阿拉泊韦的药代动力学调节
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
WO2015017382A1 (en) * 2013-07-29 2015-02-05 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
FI111730B (fi) 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US20030216303A1 (en) 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
US20040033946A1 (en) 2000-10-19 2004-02-19 Futoshi Shibasaki Cell damage inhibitor
AR036081A1 (es) * 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
US20030213603A1 (en) * 2002-05-14 2003-11-20 Fisher David B. Dual use extension apparatus for a tool
WO2004002422A2 (en) * 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
DK2241325T3 (da) * 2002-10-29 2012-04-10 Coley Pharm Group Inc Anvendelse af CPG-oligonukleotider til behandling af Hepatitis Cvirusinfektion
PL377608A1 (pl) * 2002-12-23 2006-02-06 Idenix (Cayman) Limited Sposób wytwarzania proleków 3'-nukleozydowych
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
EA012650B1 (ru) * 2004-10-01 2009-12-30 Дебиофарм С.А. ПРИМЕНЕНИЕ [D-MeAla]-[EtVal]-ЦИКЛОСПОРИНА ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИИ ГЕПАТИТА С И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ [D-MeAla]-[EtVal]-ЦИКЛОСПОРИН
WO2006071619A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment

Also Published As

Publication number Publication date
JP2008525459A (ja) 2008-07-17
NZ555143A (en) 2009-12-24
KR20070087624A (ko) 2007-08-28
RU2007128099A (ru) 2009-01-27
NO20073764L (no) 2007-09-18
MX2007007779A (es) 2007-08-14
CA2587793A1 (en) 2006-07-06
AU2005322242A1 (en) 2006-07-06
WO2006071619A1 (en) 2006-07-06
EP1830871A1 (en) 2007-09-12
US20090104149A1 (en) 2009-04-23
US7897565B2 (en) 2011-03-01
BRPI0519345A2 (pt) 2009-01-20
CN101076350A (zh) 2007-11-21
MA29098B1 (fr) 2007-12-03
IL183659A0 (en) 2007-09-20
AU2005322242B2 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
ZA200703908B (en) Compositions for HCV treatment
GB0409375D0 (en) Phytoactive composition
ZA200904425B (en) Nemathical compositions
EP1718714A4 (en) COMPOSITIONS CONTAINING A PLOTTER
ZA200703907B (en) Compounds for flaviviridae treatment
GB0416861D0 (en) Composition
GB0405406D0 (en) Anti-vaginitis compositions
GB0425795D0 (en) Composition
GB0410038D0 (en) Composition
GB0414803D0 (en) Composition
EP1726304A4 (en) COMPOSITION CONTAINING SOLIFENACIN
GB0415981D0 (en) Composition
GB0417357D0 (en) Composition
ZA200701197B (en) Compositions
GB0410140D0 (en) Compositions
ZA200704974B (en) Composition
GB0418296D0 (en) Compositions for bioremediation
GB0420627D0 (en) Monoglyceride-containing compositions
GB0417388D0 (en) Composition
HK1111614A (en) Compositions for hcv treatment
GB2418924B (en) Weathered-effect composition
GB0409598D0 (en) Composition
IL160892A0 (en) Disinfecting compositions
GB0412304D0 (en) Compositions
GB0412039D0 (en) Compositions